Send to

Choose Destination
Int J Stroke. 2015 Jun;10(4):619-26. doi: 10.1111/ijs.12157. Epub 2013 Nov 10.

REVASCAT: a randomized trial of revascularization with SOLITAIRE FR device vs. best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight-hours of symptom onset.

Author information

Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain.
Stroke Unit, Hospital Clinic Barcelona, Barcelona, Spain.
Department of Neuroradiology, Hospital Vall d'Hebron, Barcelona, Spain.
Department of Neuroradiology, Hospital de Bellvitge, Barcelona, Spain.
Department of Neurology, Hospital Josep Trueta, Girona, Spain.
Department of Neuroradiology, Hospital Clinic Barcelona, Barcelona, Spain.
Department of Neurological Surgery, UPMC, Pittsburgh, Pennsylvania, USA.
Department of Neurology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Universitat politecnica de catalunya, Barcelona, Spain.


REVASCAT is a prospective, multicenter, randomized trial seeking to establish whether subjects meeting following main inclusion criteria: age 18-80, baseline National Institutes of Health Stroke Scale ≥6, evidence of intracranial internal carotid artery or proximal (M1 segment) middle cerebral artery occlusion, Alberta Stroke Program Early Computed Tomography score of >7 on non-contrast CT or >6 on diffusion-weighted magnetic resonance imaging , ineligible for or with persistent occlusion after intravenous alteplase and procedure start within 8 hours from symptom onset, have higher rates of favorable outcome when treated with the Solitaire FR embolectomy device compared to standard medical therapy alone The primary end-point, based on intention-to-treat criteria is the distribution of modified Rankin Scale scores at 90 days. Projected sample size is 690 patients. Estimated common odds ratio is 1●615. Randomization is performed under a minimization process using age, baseline NIHSS, therapeutic window, occlusion location and investigational center. The study follows a sequential analysis (triangular model) with the first approach to test efficacy at 174 patients and subsequent analyses (if necessary) at 346, 518, and 690 subjects. Secondary end-points are infarct volume evaluated on CT at 24 h, dramatic early favorable response, defined as NIHSS of 0-2 or NIHSS improvement ≥8 points at 24 h and successful recanalization in the Solitaire arm according to the thrombolysis in cerebral infarction (TICI) classification defined as TICI 2b or 3. Safety variables are mortality at 90 days, symptomatic intracranial haemorrhage rates at 24 hours and procedure related complications.


acute stroke therapy; clinical trial; reperfusion; t-PA; therapy; treatment

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center